Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

FDA experts to vote on Abbott stent

Drug-coated device could be next to enter market as panel considers report showing strong data vs. competing stent.

Subscribe to Companies
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)
By Aaron Smith, CNNMoney.com staff writer

NEW YORK (CNNMoney.com) -- Food and Drug Administration advisers will decide this week whether they think America is ready for another drug-coated stent.

Experts will vote Thursday on Abbott Labs' (Charts, Fortune 500) experimental Xience stent, and this non-binding vote will be taken into consideration by regulators at a later date.

If Xience gets the green light, it will compete with Boston Scientific's (Charts, Fortune 500) Taxus, which is already on the market, and possibly with Medtronic's (Charts, Fortune 500) Endeavor, which in October was recommended for approval by FDA advisers. In this $3 billion market, it will also compete with the older-model bare metal stents.

Drug-coated stents have been on the U.S. market since 2003. They are wire mesh tubes inserted into arteries during angioplasty to help heart disease patients avoid blood clots. The stents have come under scrutiny for reportedly causing bleeding, though the reports are inconclusive.

Some analysts believe that Abbott has a good shot of getting Xience past the FDA because of recently released reports from Abbott. On Tuesday, Abbott released an update from an earlier study, first released in March, that showed the superiority of Xience over Taxus.

"Based on the clinical data revealed so far - and especially the clear evidence of statistically significant superiority to Boston Scientific's market-leading Taxus - we expect the panel to vote for approval of the Abbott device," said Phil Nalbone, analyst for RBC Capital Markets, in a published report.

Nalbone does not own Abbott stock, though RBC has received compensation from the company in the last 12 months for products and services other than investment banking.  To top of page

Photo Galleries
Driving the ultimate in '50s Mercedes-Benz style The SC was the car that re-introduced Mercedes-Benz as a global luxury car icon. More
Driving the world's first car Driving a replica of the 1886 Benz Patent Motorwagen, the first internal combustion automobile. More
Your guide to Cyber Monday sales This year, more Cyber Monday sales than ever start well before Monday. Here's where to shop if you don't get your fill on Black Friday. More